Can Sir(2) Regulate Cancer?

Overview

Journal Cellscience

Specialty Cell Biology

Date 2011 Sep 28

PMID 19750026

Citations 2

Authors

Pratibha V Nerurkar

Vivek R Nerurkar

Affiliations

Soon will be listed here.

Abstract

Sirtuin activators, including small molecules such as polyphenols and resveratrol, are much desired due to their potential to ameliorate metabolic disorder and delay or prevent aging. In contrast, recent studies demonstrate that targeted silencing of sirtuin 1 (SIRT1) expression or activity by the deleted in breast cancer 1 (DBC1) may be beneficial by promoting p53-induced apoptosis in cancer cells, and by sensitizing cancerous cells to radiation therapy. Negative SIRT1 regulation also alleviates gene-repression associated with fragile X mental retardation syndrome. The targeted activation or inhibition of SIRT1 activity therefore emerges as a critical point of regulation in disease pathogenesis.

Citing Articles

Simvastatin ameliorates ionizing radiation-induced apoptosis in the thymus by activating the AKT/sirtuin 1 pathway in mice.

Yang H, Huang F, Tao Y, Zhao X, Liao L, Tao X Int J Mol Med. 2017; 40(3):762-770.

PMID: 28677744 PMC: 5547942. DOI: 10.3892/ijmm.2017.3047.

Deleted in breast cancer-1 (DBC-1) in the interface between metabolism, aging and cancer.

Chini E, Chini C, Nin V, Escande C Biosci Rep. 2013; 33(4).

PMID: 23841676 PMC: 3755336. DOI: 10.1042/BSR20130062.

References

Nerurkar P, Nerurkar V . Respected Sir(2): magic target for diabetes. Cellscience. 2011; 4(4):82-96. PMC: 2890243. View

Tanno M, Sakamoto J, Miura T, Shimamoto K, Horio Y . Nucleocytoplasmic shuttling of the NAD+-dependent histone deacetylase SIRT1. J Biol Chem. 2007; 282(9):6823-32. DOI: 10.1074/jbc.M609554200. View

Nishiyama H, Hornigold N, Davies A, Knowles M . A sequence-ready 840-kb PAC contig spanning the candidate tumor suppressor locus DBC1 on human chromosome 9q32-q33. Genomics. 1999; 59(3):335-8. DOI: 10.1006/geno.1999.5891. View

Biacsi R, Kumari D, Usdin K . SIRT1 inhibition alleviates gene silencing in Fragile X mental retardation syndrome. PLoS Genet. 2008; 4(3):e1000017. PMC: 2265469. DOI: 10.1371/journal.pgen.1000017. View

Porcu M, Chiarugi A . The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension. Trends Pharmacol Sci. 2005; 26(2):94-103. DOI: 10.1016/j.tips.2004.12.009. View

Nemoto S, Fergusson M, Finkel T . Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science. 2004; 306(5704):2105-8. DOI: 10.1126/science.1101731. View

Habuchi T, LUSCOMBE M, Elder P, Knowles M . Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33. Genomics. 1998; 48(3):277-88. DOI: 10.1006/geno.1997.5165. View

Yang T, Fu M, Pestell R, Sauve A . SIRT1 and endocrine signaling. Trends Endocrinol Metab. 2006; 17(5):186-91. DOI: 10.1016/j.tem.2006.04.002. View

Ma W, Sung H, Park J, Matoba S, Hwang P . A pivotal role for p53: balancing aerobic respiration and glycolysis. J Bioenerg Biomembr. 2007; 39(3):243-6. DOI: 10.1007/s10863-007-9083-0. View

10.

Nishiyama H, Gill J, Pitt E, Kennedy W, Knowles M . Negative regulation of G(1)/S transition by the candidate bladder tumour suppressor gene DBCCR1. Oncogene. 2001; 20(23):2956-64. DOI: 10.1038/sj.onc.1204432. View

11.

Langley E, Pearson M, Faretta M, Bauer U, Frye R, Minucci S . Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J. 2002; 21(10):2383-96. PMC: 126010. DOI: 10.1093/emboj/21.10.2383. View

12.

Kim J, Chen J, Lou Z . DBC1 is a negative regulator of SIRT1. Nature. 2008; 451(7178):583-6. DOI: 10.1038/nature06500. View

13.

Lim C . SIRT1: tumor promoter or tumor suppressor?. Med Hypotheses. 2006; 67(2):341-4. DOI: 10.1016/j.mehy.2006.01.050. View

14.

Anastasiou D, Krek W . SIRT1: linking adaptive cellular responses to aging-associated changes in organismal physiology. Physiology (Bethesda). 2006; 21:404-10. DOI: 10.1152/physiol.00031.2006. View

15.

Chu F, Chou P, Zheng X, Mirkin B, Rebbaa A . Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene sirt1. Cancer Res. 2005; 65(22):10183-7. DOI: 10.1158/0008-5472.CAN-05-2002. View

16.

Zhao W, Kruse J, Tang Y, Jung S, Qin J, Gu W . Negative regulation of the deacetylase SIRT1 by DBC1. Nature. 2008; 451(7178):587-90. PMC: 2866287. DOI: 10.1038/nature06515. View

17.

Cohen H, Miller C, Bitterman K, Wall N, Hekking B, Kessler B . Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science. 2004; 305(5682):390-2. DOI: 10.1126/science.1099196. View

18.

Fulco M, Schiltz R, Iezzi S, King M, Zhao P, Kashiwaya Y . Sir2 regulates skeletal muscle differentiation as a potential sensor of the redox state. Mol Cell. 2003; 12(1):51-62. DOI: 10.1016/s1097-2765(03)00226-0. View

19.

Bensaad K, Vousden K . p53: new roles in metabolism. Trends Cell Biol. 2007; 17(6):286-91. DOI: 10.1016/j.tcb.2007.04.004. View

20.

Outeiro T, Kontopoulos E, Altmann S, Kufareva I, Strathearn K, Amore A . Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science. 2007; 317(5837):516-9. DOI: 10.1126/science.1143780. View